| Genetic Analysis of Patients With Pseudoxanthoma Elasticum (NCT00341419) | National Cancer Institute (NCI) | 2005-02-16 |
| SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery (NCT00121290) | National Cancer Institute (NCI) | 2005-02-01 |
| Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer (NCT00238121) | National Cancer Institute (NCI) | 2005-02-01 |
| EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer (NCT00107445) | National Cancer Institute (NCI) | 2005-02-01 |
| 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma (NCT00117988) | National Cancer Institute (NCI) | 2005-02-01 |
| FR901228 in Treating Patients With Metastatic Breast Cancer (NCT00098397) | National Cancer Institute (NCI) | 2005-02-01 |
| Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (NCT00112463) | National Cancer Institute (NCI) | 2005-01-07 |
| SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer (NCT00103311) | National Cancer Institute (NCI) | 2005-01-01 |
| 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy (NCT00118092) | National Cancer Institute (NCI) | 2005-01-01 |
| 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer (NCT00098956) | National Cancer Institute (NCI) | 2005-01-01 |
| Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00114179) | National Cancer Institute (NCI) | 2005-01-01 |
| SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00095628) | National Cancer Institute (NCI) | 2005-01-01 |
| FR901228 in Treating Patients With Recurrent High-Grade Gliomas (NCT00085540) | National Cancer Institute (NCI) | 2005-01-01 |
| Cilengitide in Treating Patients With Metastatic Prostate Cancer (NCT00103337) | National Cancer Institute (NCI) | 2005-01-01 |
| Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme (NCT00112866) | National Cancer Institute (NCI) | 2005-01-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Cilengitide in Treating Patients With Prostate Cancer (NCT00121238) | National Cancer Institute (NCI) | 2005-01-01 |
| Role of Gene Variation in Effectiveness of Gleevec Treatment (NCT00342056) | National Cancer Institute (NCI) | 2005-01-01 |
| Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study (NCT00100321) | National Cancer Institute (NCI) | 2004-12-21 |
| Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1 (NCT00339638) | National Cancer Institute (NCI) | 2004-12-21 |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant (NCT00114101) | National Cancer Institute (NCI) | 2004-12-15 |
| Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma (NCT00088881) | National Cancer Institute (NCI) | 2004-12-01 |
| S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer (NCT00103324) | National Cancer Institute (NCI) | 2004-12-01 |
| Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme (NCT00099060) | National Cancer Institute (NCI) | 2004-12-01 |
| Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer (NCT00118235) | National Cancer Institute (NCI) | 2004-12-01 |
| Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (NCT00104871) | National Cancer Institute (NCI) | 2004-12-01 |
| BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer (NCT00098254) | National Cancer Institute (NCI) | 2004-12-01 |
| Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer (NCT00096070) | National Cancer Institute (NCI) | 2004-12-01 |
| Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer (NCT00103298) | National Cancer Institute (NCI) | 2004-12-01 |
| Markers for Breast Cancer (NCT00339248) | National Cancer Institute (NCI) | 2004-12-01 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes (NCT00098826) | National Cancer Institute (NCI) | 2004-12-01 |
| Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units (NCT00099775) | National Cancer Institute (NCI) | 2004-12-01 |
| Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer (NCT00114244) | National Cancer Institute (NCI) | 2004-12-01 |
| Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma (NCT00093613) | National Cancer Institute (NCI) | 2004-12-01 |
| Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection (NCT00087269) | National Cancer Institute (NCI) | 2004-12-01 |
| Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer (NCT00118248) | National Cancer Institute (NCI) | 2004-12-01 |
| Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00098540) | National Cancer Institute (NCI) | 2004-12-01 |
| An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males (NCT00342771) | National Cancer Institute (NCI) | 2004-11-08 |
| Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma (NCT00098475) | National Cancer Institute (NCI) | 2004-11-03 |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00101179) | National Cancer Institute (NCI) | 2004-11-03 |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors (NCT00095459) | National Cancer Institute (NCI) | 2004-11-02 |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery (NCT00101036) | National Cancer Institute (NCI) | 2004-11-01 |
| Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer (NCT00100841) | National Cancer Institute (NCI) | 2004-11-01 |
| A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy (NCT00096551) | National Cancer Institute (NCI) | 2004-11-01 |
| Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer (NCT00095667) | National Cancer Institute (NCI) | 2004-11-01 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma (NCT00101244) | National Cancer Institute (NCI) | 2004-11-01 |
| SJG-136 in Treating Patients With Advanced Solid Tumors (NCT00103220) | National Cancer Institute (NCI) | 2004-11-01 |
| Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00096447) | National Cancer Institute (NCI) | 2004-11-01 |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (NCT00098423) | National Cancer Institute (NCI) | 2004-11-01 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT00101205) | National Cancer Institute (NCI) | 2004-11-01 |
| Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma (NCT00099047) | National Cancer Institute (NCI) | 2004-11-01 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00096005) | National Cancer Institute (NCI) | 2004-11-01 |
| Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors (NCT00100880) | National Cancer Institute (NCI) | 2004-11-01 |
| Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery (NCT00096590) | National Cancer Institute (NCI) | 2004-11-01 |
| Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (NCT00092222) | National Cancer Institute (NCI) | 2004-10-28 |
| Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease (NCT00092235) | National Cancer Institute (NCI) | 2004-10-26 |
| The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis (NCT00341172) | National Cancer Institute (NCI) | 2004-10-26 |
| Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum (NCT00094978) | National Cancer Institute (NCI) | 2004-10-25 |
| Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer (NCT00096265) | National Cancer Institute (NCI) | 2004-10-06 |
| S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00096512) | National Cancer Institute (NCI) | 2004-10-01 |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT00098631) | National Cancer Institute (NCI) | 2004-10-01 |
| CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors (NCT00098501) | National Cancer Institute (NCI) | 2004-10-01 |
| Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00096148) | National Cancer Institute (NCI) | 2004-10-01 |
| 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer (NCT00095888) | National Cancer Institute (NCI) | 2004-10-01 |
| XK469R in Treating Patients With Refractory Hematologic Cancer (NCT00095797) | National Cancer Institute (NCI) | 2004-10-01 |
| Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia (NCT00098670) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (NCT00098618) | National Cancer Institute (NCI) | 2004-10-01 |
| FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer (NCT00098527) | National Cancer Institute (NCI) | 2004-10-01 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00101296) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer (NCT00095693) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer (NCT00093626) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function (NCT00118170) | National Cancer Institute (NCI) | 2004-10-01 |
| Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors (NCT00095940) | National Cancer Institute (NCI) | 2004-10-01 |
| Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine (NCT00098813) | National Cancer Institute (NCI) | 2004-10-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00101231) | National Cancer Institute (NCI) | 2004-10-01 |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases (NCT00098605) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. (NCT00107432) | National Cancer Institute (NCI) | 2004-10-01 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (NCT00098891) | National Cancer Institute (NCI) | 2004-10-01 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (NCT00091182) | National Cancer Institute (NCI) | 2004-10-01 |
| Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery (NCT00098579) | National Cancer Institute (NCI) | 2004-10-01 |
| Decitabine in Treating Patients With Myelofibrosis (NCT00095784) | National Cancer Institute (NCI) | 2004-09-29 |
| Exercise in Women at Risk for Breast Cancer (NCT00092950) | National Cancer Institute (NCI) | 2004-09-23 |
| Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer (NCT00096278) | National Cancer Institute (NCI) | 2004-09-15 |
| Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies (NCT00451022) | National Cancer Institute (NCI) | 2004-09-13 |
| Vaccine Treatment of Kidney Cancer (NCT00089778) | National Cancer Institute (NCI) | 2004-09-10 |
| Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia (NCT00344071) | National Cancer Institute (NCI) | 2004-09-08 |
| Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development (NCT00340522) | National Cancer Institute (NCI) | 2004-09-07 |
| Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data (NCT00341939) | National Cancer Institute (NCI) | 2004-09-07 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (NCT00093821) | National Cancer Institute (NCI) | 2004-09-01 |
| S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (NCT00093418) | National Cancer Institute (NCI) | 2004-09-01 |
| Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NCT00085280) | National Cancer Institute (NCI) | 2004-09-01 |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00096122) | National Cancer Institute (NCI) | 2004-09-01 |
| Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer (NCT00091611) | National Cancer Institute (NCI) | 2004-09-01 |
| S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer (NCT00087412) | National Cancer Institute (NCI) | 2004-09-01 |
| Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00095966) | National Cancer Institute (NCI) | 2004-09-01 |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers (NCT00095563) | National Cancer Institute (NCI) | 2004-09-01 |
| Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer (NCT00096395) | National Cancer Institute (NCI) | 2004-09-01 |
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer (NCT00090545) | National Cancer Institute (NCI) | 2004-09-01 |
| UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants (NCT00098969) | National Cancer Institute (NCI) | 2004-09-01 |
| Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer (NCT00091195) | National Cancer Institute (NCI) | 2004-09-01 |